000 | 01389 a2200397 4500 | ||
---|---|---|---|
005 | 20250515192618.0 | ||
264 | 0 | _c20100203 | |
008 | 201002s 0 0 eng d | ||
022 | _a1542-6270 | ||
024 | 7 |
_a10.1345/aph.1M457 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aMarks, Anne-Bérengère | |
245 | 0 | 0 |
_aSorafenib-induced hepatic encephalopathy. _h[electronic resource] |
260 |
_bThe Annals of pharmacotherapy _cDec 2009 |
||
300 |
_a2121 p. _bdigital |
||
500 | _aPublication Type: Case Reports; Letter | ||
650 | 0 | 4 |
_aAntineoplastic Agents _xadministration & dosage |
650 | 0 | 4 |
_aBenzenesulfonates _xadministration & dosage |
650 | 0 | 4 |
_aCarcinoma, Hepatocellular _xdrug therapy |
650 | 0 | 4 | _aDose-Response Relationship, Drug |
650 | 0 | 4 |
_aHepatic Encephalopathy _xchemically induced |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 |
_aLiver Neoplasms _xdrug therapy |
650 | 0 | 4 | _aMiddle Aged |
650 | 0 | 4 |
_aNiacinamide _xanalogs & derivatives |
650 | 0 | 4 | _aPhenylurea Compounds |
650 | 0 | 4 |
_aPyridines _xadministration & dosage |
650 | 0 | 4 | _aSorafenib |
650 | 0 | 4 | _aTime Factors |
700 | 1 | _aGerard, Romain | |
700 | 1 | _aFournier, Peggy | |
700 | 1 | _aCoupe, Patrick | |
700 | 1 | _aGautier, Sophie | |
773 | 0 |
_tThe Annals of pharmacotherapy _gvol. 43 _gno. 12 _gp. 2121 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.1345/aph.1M457 _zAvailable from publisher's website |
999 |
_c19251123 _d19251123 |